Pipeline dossier

NIH & clinical-trial pipeline signals for AbbVie Inc. (ABBV)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for ABBV, mapped to public ticker ABBV (CIK 0001551152). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE2 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE2) — A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Recent SEC 8-K filings

2026-08-05 — 8-K 8.01,9.01 view ↗
2026-07-31 — 8-K 2.02,9.01 view ↗
2026-07-06 — 8-K 2.02,9.01 view ↗
2026-06-22 — 8-K 7.01,9.01 view ↗
2026-05-12 — 8-K 5.07 view ↗

JSON API for this entity →